Narcan Now Available Over the Counter to Reverse Opioid Overdoses

Safety
Published

Narcan, the trade name for Naloxone HCl Nasal Spray, was approved for over-the-counter (OTC) nonprescription use by the U.S. Food and Drug Administration in March, becoming the first naloxone product approved for use without a prescription. Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for opioid overdose.

Emergent BioSolutions has announced that shipments of its over the counter, original prescription strength NARCAN® Nasal Spray 4mg are now being delivered to leading pharmacies and grocery stores, as well as online retailers.

Drug overdose persists as a major public health issue in the United States, with more than 101,750 reported fatal overdoses occurring in the 12-month period ending in October 2022, primarily driven by synthetic opioids like illicit fentanyl. Construction workers account for nearly 23% of all opioid overdose deaths. Many of these happened on the job.

When someone is having an opioid overdose, the receptors in their brain get filled and overstimulated by opioids and when these receptors are full or are “maxed out,” your brain tells your body to slow down or even stop your breathing. Naloxone works to reverse this process. It works by binding with and blocking opioid receptors to rapidly reverse the effects of opioid overdose.

According to Emergent, last year, approximately every seven minutes one life was lost due to an opioid overdose, and today it is the leading cause of accidental death in the United States. The average response time for emergency services to arrive is approximately 10 minutes.

Having NARCAN® Nasal Spray in a first-aid kit on a job site, or carrying it on the go in case of an opioid emergency, can make a difference and help reverse the effects of opioids while waiting for emergency personnel to arrive.

The manufacturer’s suggested retail price of NARCAN® Nasal Spray is $44.99 per two-dose carton, roughly $22.50 per dose.

Learn more about Naloxone. NAHB also has resources to address the opioid crisis in construction.

Subscribe to NAHBNow

Log in or create account to subscribe to notifications of new posts.

Log in to subscribe

Latest from NAHBNow

Economics

Sep 24, 2025

New Home Sales Post Unexpected Large Gain in August

Sales of newly built single-family homes jumped 20.5% higher in August, to a seasonally adjusted annual rate of 800,000 from an upwardly revised reading in July, according to newly released data from the U.S. Department of Housing and Urban Development and the U.S. Census Bureau. The pace of new home sales is up 15.4% from a year earlier. The three-month moving average of new home sales was 713,000, an increase from the 656,000 in July. New home sales remain down 1.4% on a year-to-date basis.

Membership | Legal

Sep 23, 2025

NAHB Members: Join the Housing Industry’s Attorney Network

Doing business with fellow members is a core value of the NAHB Federation. To strengthen that commitment, NAHB is building a network of attorney members to assist peers with legal issues.

View all

Latest Economic News

Economics

Sep 24, 2025

Single-Family Construction Loan Volume Falls Back

The NAHB Land Acquisition, Development and Construction (AD&C) loan survey in the second quarter reported tightening credit conditions for builders. Consequently, FDIC data reporting the outstanding volume of 1-4 family construction loans fell in the second quarter.

Economics

Sep 23, 2025

Beyond the Official Unemployment Rate: A Deep Dive into U.S. Unemployment

In August, the official, or standardly referenced, unemployment rate rose slightly to 4.3%, up from 4.2% in July. This marks the highest level in nearly four years, though it remains historically low.

Economics

Sep 22, 2025

Single-Family Homes Are Built Faster in 2024

Building a new single-family home took less time in 2024 compared to the previous two years. On average, it now takes 9.1 months from start to finish.